Skip to main content

Table 2 Univariable predictors of post-ablation recurrence of atrial fibrillation are shown

From: The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial

  Aggressive Standard Whole cohort
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age (years) 0.99 (0.96–1.03) 0.69 1.03 (1.00–1.07) 0.04 1.01 (0.99–1.03) 0.35
Sex (Female) 1.17 (0.63–2.18) 0.62 1.4 (0.78–2.5) 0.26 1.29 (0.84–1.96) 0.25
Persistent AF 1.06 (0.62–1.81) 0.83 0.75 (0.43–1.3) 0.3 1.13 (0.77–1.66) 0.54
Duration of AF 1.00 (0.99–1.01) 0.81 1.00 (1.00–1.01) 0.07 1.00 (1.00–1.01) 0.29
Baseline SBP (mmHg) 1.03 (1.00–1.05) 0.02 1.01 (0.99–1.03) 0.38 1.02 (1.00–1.03) 0.02
Baseline SBP ≥ 140 mmHg 2.14 (1.22–3.73) 0.01 0.83 (0.48–1.43) 0.49 0.76 (0.51–1.11) 0.15
Diabetes 0.76 (0.34–1.67) 0.49 1.58 (0.71–3.51) 0.26 1.04 (0.59–1.82) 0.89
LA Size 1 (0.95–1.05) 0.91 0.99 (0.94–1.04) 0.74 0.99 (0.96–1.03) 0.74
Baseline NT-proBNP ≥ 280 (pg/ml) 1.98 (1.13–3.51) 0.02 1.00 (0.55–1.83) 0.99 1.40 (0.92–2.12) 0.10
Log-NT-proBNP (pg/ml) 1.28 (1.01–1.62) 0.04 0.94 (0.74–1.20) 0.62 1.09 (0.92–1.29) 0.31
CRP 1.00 (0.95–1.05) 0.89 0.99 (0.92–1.07) 0.82 1.00 (0.96–1.04) 0.81
  1. Significant results (p < 0.05) are bolded
  2. All characteristics were measured at time of randomization
  3. AF, atrial fibrillation; SBP, systolic blood pressure; LVEF, left ventricular ejection fraction; LA, left atrium; CRP, C-reactive protein